pg电子官网

关于我们
研发服务
服务平台
客户中心
新闻资讯
投资者关系
人力资源
EN
×
EN

  • 业务咨询

    中国：

    Email: marketing@shtongxi.com.cn

    业务咨询专线：400-780-8018

    （仅限服务咨询，其他事宜请拨打川沙总部电话）

    川沙总部电话: +86 (21) 5859-1500

    海外：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在线留言×
点击切换
Customer Center
客户中心
Jun 28,2023
TAK-931是一种高度特异性的CDC7抑制剂，具有抗肿瘤功效，体内药效研究通过pg电子官网进行
In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.
查看更多
TAK-931是一种高度特异性的CDC7抑制剂，具有抗肿瘤功效，体内药效研究通过pg电子官网进行
Jun 28,2023
GS-5801是一种有效的KDM5抑制剂，具有抗HBV活性，GS-5801通过pg电子官网合成
GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.
查看更多
GS-5801是一种有效的KDM5抑制剂，具有抗HBV活性，GS-5801通过pg电子官网合成
Jun 28,2023
QF-036是一种高效的HIV-1抑制剂，具有良好的和药代动力学特性，PK研究通过pg电子官网进行
The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.
查看更多
QF-036是一种高效的HIV-1抑制剂，具有良好的和药代动力学特性，PK研究通过pg电子官网进行
Jun 28,2023
设计合成一种新型选择性的口服有效苏氨酸酪氨酸激酶 (TTK) 抑制剂，PK研究均通过pg电子官网进行
TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon.
查看更多
设计合成一种新型选择性的口服有效苏氨酸酪氨酸激酶 (TTK) 抑制剂，PK研究均通过pg电子官网进行
Jun 28,2023
TR-107是人类线粒体蛋白酶ClpP的有效激活剂，PK分析通过pg电子官网进行
The pharmacokinetic properties of TR‐107 were compared with other known ClpP activators including ONC201 and ONC212. TR‐107 displayed excellent exposure and serum t1/2 after oral administration. Pharmacokinetic analysis were evaluated for pharmacokinetic properties in ICR mice by Medicilon.
查看更多
TR-107是人类线粒体蛋白酶ClpP的有效激活剂，PK分析通过pg电子官网进行
Jun 28,2023
SKLB-197是一种有效且高度选择性的ATR抑制剂，PK研究通过pg电子官网进行
SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.
查看更多
SKLB-197是一种有效且高度选择性的ATR抑制剂，PK研究通过pg电子官网进行
Jun 28,2023
H11-HLE是一种工具分子，可用于研究Fc在介导免疫检查点治疗中的作用，具有抗肿瘤功效
Immune checkpoint inhibition therapies have been used for multiple cancer research. H11-HLE is a tool molecule that allows the interrogation of the contribution of Fc in mediating immune checkpoint therapy. Half-life extended H11 (H11-HLE) induces potent anti-tumor efficacy in mouse syngeneic tumor models.
查看更多
H11-HLE是一种工具分子，可用于研究Fc在介导免疫检查点治疗中的作用，具有抗肿瘤功效
Jun 28,2023
JND003是一种新型选择性ERRα激动剂，可缓解非酒精性脂肪肝和胰岛素抵抗，PK和组织分布测定通过pg电子官网进行
Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent forms of chronic liver diseases. Estrogen-related receptor alpha (ERRα) is a viable target for NAFLD.
查看更多
JND003是一种新型选择性ERRα激动剂，可缓解非酒精性脂肪肝和胰岛素抵抗，PK和组织分布测定通过pg电子官网进行
Jun 28,2023
发现用于局部治疗牛皮癣的新型PDE4抑制剂，小鼠、大鼠和人肝微粒体的代谢稳定性实验通过pg电子官网测定
Psoriasis is a common immune-mediated skin disorder manifesting in abnormal skin plaques, and PDE4 is an effective target for the treatment of inflammatory diseases such as psoriasis.
查看更多
发现用于局部治疗牛皮癣的新型PDE4抑制剂，小鼠、大鼠和人肝微粒体的代谢稳定性实验通过pg电子官网测定
Jun 28,2023
研究用于肺癌和黑色素瘤细胞肺转移的选择性PAK4抑制剂的合成，此选择性PAK4抑制剂的PK研究通过pg电子官网进行
The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic cancer. The pharmacokinetic study of Compound 55 was carried out by Medicilon.
查看更多
研究用于肺癌和黑色素瘤细胞肺转移的选择性PAK4抑制剂的合成，此选择性PAK4抑制剂的PK研究通过pg电子官网进行
×
搜索验证
点击切换
友情链接: